RPRX up +56.90% percent right now. $RPRX High is at 10.25 and the Low 7.66 with current volume of 8,183,000.
Recent News posted below.
RPRX Repros Therapeutics Inc Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 33.90 (+0.30), PERI: 5.75 (-0.35), UNXL: 5.31 (+0.77), TREE: 47.03 (+3.12), SSRI: 5.20 (+0.88), STMP: 42.92 (+0.93), RPRX: 10.12 (+3.67), NYNY: 7.74 (-0.22), SHLD: 42.81 (+10.14), AREX: 10.73 (+1.88), PGNX: 5.37 (+0.76), ECYT: 6.03 (-0.46), SSO.TO: 5.90 (+0.95), SGMA: 7.21 (-0.64), SW.TO: 38.39 (-0.04), PLNR: 6.40 (+0.01)
Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 1.05 (+0.19), AMSC: 1.17 (-0.19), RPRX: 10.12 (+3.67), SHLD: 42.81 (+10.14), STAY: 18.30 (-5.00)
Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 10.12 (+3.67)
Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 10.12 (+3.67)
Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 91.06 (-3.49), PBH: 32.79 (-4.53), RPRX: 10.12 (+3.67), HSP: 56.32 (-0.32)
63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 10.12 (+3.67)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.04 (+0.41), PTX: 9.09 (-0.17), AKRX: 36.59 (-1.29), RPRX: 10.12 (+3.67), NKTR: 13.35 (-0.21)
Repros to Webcast Investor and Analyst Day on October 31st
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York City on Friday, October 31, 2014 beginning at 7:30 a.m. Eastern Time.
RPRX: 10.12 (+3.67)
Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 10:18AM CDT
Will Amgen (AMGN) go the Abbott (ABT) way and split into two separate companies?
PCYC: 133.49 (-3.63), NPSP: 27.49 (+0.15), RPRX: 10.12 (+3.67), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), REGN: 377.84 (+0.90), CELG: 106.45 (-0.69)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX
PR Newswire - Mon Oct 20, 12:33PM CDT
Levi & Korsinsky, LLP is investigating Repros Therapeutics Inc. ("Repros" or the "Company"
(NasdaqCM: RPRX) in connection with possible violations of federal securities laws.
RPRX: 10.12 (+3.67)
INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Oct 20, 9:36AM CDT
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. ("Repros Therapeutics" or the "Company" (NASDAQ: RPRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning the Company's business and financial prospects.
RPRX: 10.12 (+3.67)
Repros Therapeutics Down 64.6% Since SmarTrend Downtrend Call (RPRX)
Comtex SmarTrend(R) - Mon Oct 20, 9:08AM CDT
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 64.61% as of today's recent price of $6.32.
RPRX: 10.12 (+3.67)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc.
PR Newswire - Mon Oct 20, 8:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Repros Therapeutics, Inc. ("Repros Therapeutics" or the "Company" (NasdaqCM: RPRX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
RPRX: 10.12 (+3.67)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
PR Newswire - Fri Oct 17, 7:28PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Repros Therapeutics Inc. ("Repros" or the "Company" (NASDAQ: RPRX).
RPRX: 10.12 (+3.67)
GE and Urban Outfitters are big market movers
AP - Fri Oct 17, 3:31PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
URBN: 31.18 (+0.02), GE: 26.41 (+0.05), CLV: 10.77 (+0.44), RPRX: 10.12 (+3.67), CLF: 11.17 (+0.63), ATHN: 123.82 (-1.94), MS: 35.66 (+0.35)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX
Business Wire - Fri Oct 17, 2:17PM CDT
The Rosen Law Firm announces that it is investigating potential securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
RPRX: 10.12 (+3.67)
Recent News posted below.
RPRX Repros Therapeutics Inc Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 33.90 (+0.30), PERI: 5.75 (-0.35), UNXL: 5.31 (+0.77), TREE: 47.03 (+3.12), SSRI: 5.20 (+0.88), STMP: 42.92 (+0.93), RPRX: 10.12 (+3.67), NYNY: 7.74 (-0.22), SHLD: 42.81 (+10.14), AREX: 10.73 (+1.88), PGNX: 5.37 (+0.76), ECYT: 6.03 (-0.46), SSO.TO: 5.90 (+0.95), SGMA: 7.21 (-0.64), SW.TO: 38.39 (-0.04), PLNR: 6.40 (+0.01)
Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 1.05 (+0.19), AMSC: 1.17 (-0.19), RPRX: 10.12 (+3.67), SHLD: 42.81 (+10.14), STAY: 18.30 (-5.00)
Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 10.12 (+3.67)
Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 10.12 (+3.67)
Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 91.06 (-3.49), PBH: 32.79 (-4.53), RPRX: 10.12 (+3.67), HSP: 56.32 (-0.32)
63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 10.12 (+3.67)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.04 (+0.41), PTX: 9.09 (-0.17), AKRX: 36.59 (-1.29), RPRX: 10.12 (+3.67), NKTR: 13.35 (-0.21)
Repros to Webcast Investor and Analyst Day on October 31st
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York City on Friday, October 31, 2014 beginning at 7:30 a.m. Eastern Time.
RPRX: 10.12 (+3.67)
Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 10:18AM CDT
Will Amgen (AMGN) go the Abbott (ABT) way and split into two separate companies?
PCYC: 133.49 (-3.63), NPSP: 27.49 (+0.15), RPRX: 10.12 (+3.67), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), REGN: 377.84 (+0.90), CELG: 106.45 (-0.69)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX
PR Newswire - Mon Oct 20, 12:33PM CDT
Levi & Korsinsky, LLP is investigating Repros Therapeutics Inc. ("Repros" or the "Company"
(NasdaqCM: RPRX) in connection with possible violations of federal securities laws. RPRX: 10.12 (+3.67)
INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Oct 20, 9:36AM CDT
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. ("Repros Therapeutics" or the "Company"
(NASDAQ: RPRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning the Company's business and financial prospects. RPRX: 10.12 (+3.67)
Repros Therapeutics Down 64.6% Since SmarTrend Downtrend Call (RPRX)
Comtex SmarTrend(R) - Mon Oct 20, 9:08AM CDT
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 64.61% as of today's recent price of $6.32.
RPRX: 10.12 (+3.67)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc.
PR Newswire - Mon Oct 20, 8:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Repros Therapeutics, Inc. ("Repros Therapeutics" or the "Company"
(NasdaqCM: RPRX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. RPRX: 10.12 (+3.67)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
PR Newswire - Fri Oct 17, 7:28PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Repros Therapeutics Inc. ("Repros" or the "Company"
(NASDAQ: RPRX). RPRX: 10.12 (+3.67)
GE and Urban Outfitters are big market movers
AP - Fri Oct 17, 3:31PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
URBN: 31.18 (+0.02), GE: 26.41 (+0.05), CLV: 10.77 (+0.44), RPRX: 10.12 (+3.67), CLF: 11.17 (+0.63), ATHN: 123.82 (-1.94), MS: 35.66 (+0.35)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX
Business Wire - Fri Oct 17, 2:17PM CDT
The Rosen Law Firm announces that it is investigating potential securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
RPRX: 10.12 (+3.67)
